TPThibault Petit

Thibault Petit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thibault Petit has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Jan A. Staessen

    Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    3 shared publications
  • Fang-Fei Wei

    Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium

    2 shared publications
  • Jan Verwerft

    Jessa Hospital

    2 shared publications
  • Jens-Uwe Voigt

    Department of Cardiovascuar Diseases, University Hospitals Leuven , Herestraat 49, Leuven 3000

    2 shared publications
  • Lieven Herbots

    Jessa Hospital

    2 shared publications
  • Lotte Jacobs

    Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium

    2 shared publications

Latest Publications

  • Pulmonary hypertension during exercise underlies unexplained exertional dyspnoea in patients with Type 2 diabetes

    by Tin Gojevic, Lisa Van Ryckeghem, Siddharth Jogani, Ines Frederix, Elise Bakelants, Thibault Petit, Sarah Stroobants, Paul Dendale, Virginie Bito, Lieven Herbots, et al.

    To compare the cardiac function and pulmonary vascular function during exercise between dyspnoeic and non-dyspnoeic patients with Type 2 diabetes mellitus (T2DM). Forty-seven T2DM patients with unexplained dyspnoea and 50 asymptomatic T2DM patients underwent exercise echocardiography combined with ergospirometry. Left ventricular (LV) function [stroke volume, cardiac output (CO), LV ejection fraction, systolic annular velocity (s′)], estimated LV filling pressures (E/e′), mean pulmonary arterial pressures (mPAPs) and mPAP/COslope were assessed at rest, low- and high-intensity exercise with colloid contrast. Groups had similar patient characteristics, glycemic control, stroke volume, CO, LV ejection fraction, and E/e′ (P > 0.05). The dyspnoeic group had significantly lower systolic LV reserve at peak exercise (s′) (P = 0.021) with a significant interaction effect (P < 0.001). The dyspnoeic group also had significantly higher mPAP and mPAP/CO at rest and exercise (P < 0.001) with significant interaction for mPAP (P < 0.009) and insignificant for mPAP/CO (P = 0.385). There was no significant difference in mPAP/COslope between groups (P = 0.706). However, about 61% of dyspnoeic vs. 30% of non-dyspnoeic group had mPAP/COslope > 3 (P = 0.009). The mPAP/COslope negatively predicted V̇O2peak in dyspneic group (β = −1.86, 95% CI: −2.75, −0.98; multivariate model R2:0.54). Pulmonary hypertension and less LV systolic reserve detected by exercise echocardiography with colloid contrast underlie unexplained exertional dyspnoea and reduced exercise capacity in T2DM.


  • Impaired biventricular contractile reserve in patients with diastolic dysfunction: insights from exercise stress echocardiography

    by Mathias Claeys, Thibault Petit, Andre La Gerche, Lieven Herbots, Piet Claus, Ruben De Bosscher, Walter Droogne, Johan Van Cleemput, Jens Uwe Voigt, Marion Delcroix, et al.

    Cardiac output limitation is a fundamental feature of heart failure with preserved ejection fraction (HFpEF) but the relative contribution of its determinants in symptomatic vs. asymptomatic stages are not well characterized. We aimed to gain insight into disease mechanisms by performing comprehensive comparative non-invasive exercise imaging in patients across the disease spectrum. We performed bicycle stress echocardiography in 10 healthy controls, 13 patients with hypertensive left ventricular (LV) concentric remodelling and asymptomatic diastolic dysfunction (HTDD), 15 HFpEF patients, and 15 subjects with isolated right ventricular (RV) dysfunction secondary to chronic thromboembolic pulmonary hypertension (CTEPH). During exercise, ventricular performance differed across the groups (all P ≤ 0.01 for interaction). Notably in controls, LV and RV function significantly increased (all P < 0.05) while both LV systolic and diastolic reserve were significantly reduced in HFpEF patients. Likewise, RV systolic reserve was also impaired in HFpEF but not to the extent of CTEPH patients (P < 0.001 between groups). HTDD patients behaved as an intermediary group with borderline LV systolic and diastolic reserve and reduced RV systolic reserve. The increased pulmonary vascular (PV) load in HFpEF and CTEPH patients in combination with impaired RV reserve resulted in RV–pulmonary artery uncoupling during exercise. The multifaceted decline of cardiac and PV function accompanying disease progression in HFpEF is unmasked by exercise and already emerges in preclinical disease. The revelation of these subtle abnormalities during exercise illustrates the benefit of exercise imaging and creates new prospects for early diagnosis and management.


  • Open Access

    Right Ventricular and Cyclic Guanosine Monophosphate Signalling Abnormalities in Stages B and C of Heart Failure with Preserved Ejection Fraction

    by Thibault Petit, Guido Claessen, Mathias Claeys, Andre La Gerche, Piet Claus, Stefan Ghysels, Marion Delcroix, Agnieszka Ciarka, Walter Droogne, Johan Van Cleemput, et al.

    Aims Identifying early right ventricular (RV) dysfunction and impaired vasodilator reserve is challenging in heart failure with preserved ejection fraction (HFpEF). We hypothesized that cardiac magnetic resonance (CMR)-based exercise imaging and serial cyclic guanosine monophosphate (cGMP) measurements can identify dynamic RV-arterial uncoupling and responsiveness to pulmonary vasodilators at early stages of the HFpEF syndrome. Methods and results Patients with HFpEF (n = 16), impaired left ventricular relaxation due to concentric remodelling (LVCR, n = 7), and healthy controls (n = 8) underwent CMR at rest and during supine bicycle exercise with simultaneous measurements of central haemodynamics and circulating cGMP levels, before and after oral administration of 50 mg sildenafil. At rest, mean pulmonary artery pressures (mPAP) were higher in HFpEF, compared with LVCR and controls (27 ± 2, 18 ± 1, and 11 ± 1, respectively; P = 0.01), whereas biventricular volumes, heart rate, and stroke volume were similar. During exercise, LVCR and HFpEF had a greater increase in the ratio of mPAP over cardiac output than controls (5.50 ± 0.77 and 6.34 ± 0.86 vs. 2.24 ± 0.55 in controls, P = 0.005). The ratio of peak exercise to rest RV end-systolic pressure-volume, a surrogate of RV contractility, was significantly reduced in LVCR and HFpEF (2.32 ± 0.17 and 1.56 ± 0.08 vs. 3.49 ± 0.35 in controls, P < 0.001) and correlated with peak exercise VO2 (R2 = 0.648, P < 0.001). cGMP levels increased with exercise across the HFpEF spectrum (P < 0.05 vs. baseline), except when postcapillary pulmonary hypertension was present at rest (P = 0.73 vs. baseline). A single sildenafil administration failed to increase circulating cGMP levels and did not improve RV performance. Conclusion Exercise CMR identifies impaired RV-arterial coupling at an early stage of HFpEF. Circulating cGMP levels phenocopy the haemodynamic spectrum in HFpEF but fail to increase after phosphodiesterase type 5 inhibition, endorsing the need for alternative interventions to increase cGMP signalling in HFpEF.


  • Open Access

    Ventricular Assist Devices in Adults with Failing Systemic Right Ventricle: The Importance of Concomitant Tricuspid Valve Replacement

    by O. Gonzalez Fernandez, F. De Rita, L. Coats, D. Crossland, M. Nassar, A. Hermuzi, B. Santos Lopez, A. Woods, N. Robinson-Smith, T. Petit, et al.

  • Open Access

    Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population

    by Zhen-Yu Zhang, Susana Ravassa, Wen-Yi Yang, Thibault Petit, Martin Pejchinovski, Petra Zürbig, Begoña López, Fang-Fei Wei, Claudia Pontillo, Lutgarde Thijs, et al.

    Current knowledge on the pathogenesis of diastolic heart failure predominantly rests on case-control studies involving symptomatic patients with preserved ejection fraction and relying on invasive diagnostic procedures including endomyocardial biopsy. Our objective was to gain insight in serum and urinary biomarkers reflecting collagen turnover and associated with asymptomatic diastolic LV dysfunction. We randomly recruited 782 Flemish (51.3% women; 50.5 years). We assessed diastolic LV function from the early and late diastolic peak velocities of the transmitral blood flow and of the mitral annulus. By sequencing urinary peptides, we identified 70 urinary collagen fragments. In serum, we measured carboxyterminal propeptide of procollagen type 1 (PICP) as marker of collagen I synthesis and tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1), an inhibitor of collagen-degrading enzymes. In multivariable-adjusted analyses with Bonferroni correction, we expressed effect sizes per 1-SD in urinary collagen I (uCI) or collagen III (uCIII) fragments. In relation to uCI fragments, e’ decreased by 0.183 cm/s (95% confidence interval, 0.017 to 0.350; p = 0.025), whereas E/e’ increased by 0.210 (0.067 to 0.353; p = 0.0012). E/e’ decreased with uCIII by 0.168 (0.021 to 0.316; p = 0.018). Based on age-specific echocardiographic criteria, 182 participants (23.3%) had subclinical diastolic LV dysfunction. Partial least squares discriminant analysis contrasting normal vs. diastolic LV dysfunction confirmed the aforementioned associations with the uCI and uCIII fragments. PICP and TIMP-1 increased in relation to uCI (pp≤0.0006). Diastolic LV dysfunction was associated with higher levels of TIMP-1 (653 vs. 696 ng/mL; p = 0.013). In a general population, the non-invasively assessed diastolic LV function correlated inversely with uCI and serum markers of collagen I deposition, but positively with uCIII. These observations generalise previous studies in patients to randomly recruited people, in whom diastolic LV function ranged from normal to subclinical impairment, but did not encompass overt diastolic heart failure.


  • [PP.07.05] PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1 IS NOT A SUSCEPTIBILITY GENE FOR CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION

    by W. Yang, T. Petit, N. Cauwenberghs, Z. Zhang, L. Thijs, E. Salvi, B. Izizi, C. Vandenbriele, F. Wei, Y. Gu, et al.

    Objective: Platelet Endothelial Aggregation Receptor 1 (PEAR1), a membrane protein highly expressed in platelets and endothelial cells, mediates platelet contact-induced activation and sustained platelet aggregation. Among patients with coronary heart disease on antiplatelet agents, PEAR1 rs12041331 A allele carriers experienced more adverse cardiovascular outcomes and had higher death rates than GG homozygotes. We investigated whether in a white population genetic variation in PEAR1 predicts cardiovascular outcome. Design and method: Among 1938 participants enrolled in the Flemish Study on Environment, Genes and Health Outcomes (51.3% women; mean age 43.6 years), we genotyped 9 SNPs and reconstructed haplotypes in PEAR1, measured baseline cardiovascular risk factors, and recorded fatal and non-fatal outcomes. For SNPs, we contrasted cardiovascular disease incidence of minor-allele heterozygotes and homozygotes (variant) vs. major-allele homozygotes (reference) and for haplotypes carriers vs. non-carriers. Results: Among these 1938 participants, 238 died and 182 experienced a major cardiovascular endpoint. In adjusted analyses, we accounted for baseline variables, including sex, age, body mass index, systolic pressure, the total-to-HDL cholesterol ratio, smoking and drinking, antihypertensive drug treatment and history of cardiovascular disease. The hazard ratios expressing the risk of death or of a cardiovascular endpoint in minor allele carriers vs. major allele homozygotes of 10 PEAR1 SNPs, including rs12041331, ranged from 0.95 to 1.03 (P > = 0.38) and from 0.72 to 1.36 (P > = 0.23), respectively. The multivariable-adjusted hazard ratios expressing the risk in carriers vs. non-carriers of three haplotypes with frequency > = 15% ranged from 0.89 to 1.09 (P > = 0.38) for mortality and from 0.67 to 1.26 (P > = 0.20) for a cardiovascular complications. These results were not influenced by intake of antiplatelet drugs, non-steroidal anti-inflammatory drugs, or both (P-values for interaction > = 0.27). Conclusions: In a white population, we could not replicate previous reports suggesting that PEAR1 might be a susceptibility gene for cardiovascular complications. Our findings were consistent irrespective of the use of antiplatelet agents.

  • Open Access

    Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies

    by Fang-Fei Wei, Nadja E.A. Drummen, Aletta E. Schutte, Lutgarde Thijs, Lotte Jacobs, Thibaut Petit, Wen-Yi Yang, Wayne Smith, Zhen-Yu Zhang, Yu-Mei Gu, et al.